



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.

10/633,738

Applicant(s)

Myatt et al.

Filed

August 4, 2003

Title

Compositions Comprising A Defined

Polysaccharide Component

TC/A.U.

1623

Examiner

Everett White

Conf. No.

5595

Docket No.

9151R

Customer No.

27752

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents

P. O. Box 1450

Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, record is being made on the attached Form PTO/SB08 of documents which the Patent Office may wish to consider in connection with examination of the above-identified patent application. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case. As provided in §1.97(g), no representation is made or intended that a thorough art search was made. As provided in 37 C.F.R. §1.97(h), this Information Disclosure Statement does not constitute an admission of any kind, and specifically is not an admission that the documents listed on attached form PTO/SB08 are, or are considered to be, material to the patentability of the above-identified patent application, as defined in 37 C.F.R. §1.56(b).

1. 37 C.F.R. §1.97(b)(1) - U.S. Direct (use when filing IDS with nonprovisional patent application, or with Request for Continued Examination (RCE); or within 3 months of filing a nonprovisional patent application)

This information disclosure statement, submitted under 37 C.F.R. §1.97(b)(1), is being filed with the patent application, with a Request for Continued Examination or within three months of the filing date of a national application. Therefore, no fee is believed to be due.

2. [] 37 C.F.R. §1.97(b)(3) - (use when filing IDS more than 3 months after filing a nonprovisional patent application, but prior to receipt of first Office Action)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(b)(3). An Office Action on the merits in the present application has not yet been received. Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter (or a fee transmittal form) is enclosed to facilitate charging of the fee, if necessary.

3. [] 37 C.F.R. §1.97(b)(4) - (use when filing IDS prior to receipt of first Office Action after the filing of a Request for Continued Examination (RCE) under §1.114)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(b)(4). A first Office Action after filing a Request For Continued Examination (RCE) has not yet been received. Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter (or a fee transmittal form) is enclosed to facilitate charging of the fee, if necessary.

4. [X] 37 C.F.R. §1.97(c) with fee payment - (use when filing IDS after receipt of first Office Action, and before receipt of Final Office Action, Notice of Allowance, or an action that otherwise closes prosecution)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(c). A final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in the application (e.g., *Ex parte Quayle*) has not been received as of the date of this submission. I hereby elect to pay the fee set forth in 37 C.F.R. §1.17(p). Please charge the fee set forth in 37 C.F.R. §1.17(p) to Deposit Account Number 16-2480 in the name of The Procter & Gamble Company. A duplicate copy of this letter (or a fee transmittal form) is enclosed to facilitate the charging of the fee.

5. Information to be Considered with Continued Prosecution Application (CPA) Filing (use when filing IDS with a Continued Prosecution Application (CPA) for Design Case). This information disclosure statement is being filed with a Continued Prosecution Application (CPA) filed under 37 C.F.R. 1.53(d).

ADDITIONAL ITEMS TO BE NOTED BY THE EXAMINER:

[] (1) (For use with applications filed prior to or on June 30, 2003.) Copies of the
cited documents are enclosed.
OR
[] (2) (For use with applications filed after June 30, 2003.) In accordance with 3
C.F.R. §1.98(a)(2), copies of only foreign patent documents and non-patent literature are
enclosed.
OR
[] (3) All of the cited references were previously cited by or submitted to the USPTO in
prior application Case No, U.S. Patent Application Serial No, filed Priority i
claimed to said application under 35 U.S.C. §120. Accordingly, copies of previously submitted
references are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d). It is
respectfully requested that the cited documents be carefully considered by the Examiner and
made of record in this case.
OR
[] (4) Copies of all said documents, except Cite Numbers, were submitted
and considered in parent application U.S. Patent Application Serial No, filed
Priority is claimed to said application under 35 U.S.C. §120. Accordingly, copies of
previously submitted references are not provided with this Statement, pursuant to 37 C.F.R
§1.98(d). Copies of references not previously submitted are enclosed. It is respectfully
requested that the cited documents be carefully considered by the Examiner and made of record
in this case.
[] (5) Pursuant to 37 C.F.R. §1.98(c), a concise explanation of the relevance of each cited
reference that is not in the English language is provided.

[] (6) It is respectfully requested that the Examiner consider and make of record the copending applications listed on the attached page.

[X] Additional information attached is generated from the International Search Report.

Respectfully submitted,

THE PROCTER & GAMBLE COMPANY

Signature

Tahira Sharon Jayasuriya

Typed or printed name Registration No. 41,501

(513) 622-0291

Date: November 29, 2004 **Customer No. 27752**(9188R SUPPL IDS (Last Revised 10/06/2004)

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to resp	ond to a collection of information unles	s it contains a valid OMB control number		
ubstitute for form 1449A/PTO	COMPLETE IF KNOWN			
DEC 0 1 2004 (E)	Application Number	10/633,738		
INFORMATION DISCLOSURE	Confirmation Number	5595		
STATEMENT BY APPLICANT	Filing Date	August 4, 2003		
(use as many sheets as necessary)	First Named Inventor	Myatt et al.		
	Group Art Unit	1623		
	Examiner Name	Everett White		
SHEET lof l	Attorney Docket Number	9151R		

U. S. PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No.1	DOCUMENT NUMBER Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		US-4,321,263	03/23/82	Powell et al.	
		US-4,548,806	10/22/85	Colliopoulos et al.	
		US-4,999,200	03/12/1991	Angel Cassilan	
		US-5,219,570	06/15/93	Melvin A. Barbera	
		US-5,320,847	06/14/94	Valentine et al.	
		US-			
		US-			
		UŚ-			
		US-	·		
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No.1	FOREIGN PATENT DO Country Code ³ Number ⁴	CUMENT Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T°
		W0 00/74689A1		12/14/2000	Wisconsin Alumni Research		
		W0 03/099311A1		12/04/2003	The Procter & Gamble Co.		
		W0 97/06808A1		02/27/1997	Xyprofin OY		
· · · · · · · · · · · · · · · · · · ·							
				<u></u>			
EXAMINE	3				DATE CONSIDERED		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). ²See Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 37 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

9151R SUPPI. PTO-SB08 (Revised for P&G use 10/8/2003)